A cDNA encoding a functional bradykinin receptor was isolated from a rat uterus library by a clonal selection strategy using Xenopus laevis oocytes to assay for expression of bradykinin responses. The predicted protein is homologous to the seven transmembrane G protein-coupled superfamily of receptors. Bradykinin and its analogs stimulate a Cl current in oocytes expressing the receptor with the rank order of potency: bradykinin Lys-bradykinin > [Tyr8]-bradykinin >> [Phe6Jbradykinin. This is the rank order of potency observed for these compounds in competitive binding assays on soluble receptor from rat uterus. Des-Arg9-bradykinin (10 pAM) elicits no response when applied to oocytes expressing the receptor; thus, the cDNA encodes a B2 type bradykinin receptor. [This8,DPhe7Jbradykinin, where Thi is I3-(2-thienyl)-alanine, is a very weak partial agonist and inhibits the bradykinin-mediated ion flux, suggesting the cDNA encodes a smooth muscle, rather than a neuronal, B2 receptor subtype. Receptor message has a distribution consistent with previous reports of bradykinin function and/or binding in several tissues and is found in rat uterus, vas deferens, kidney, lung, heart, ileum, testis, and brain. Receptor subtypes are a possibility because several tissues contain two or three message species (4.0, 5.7, and 6.5 kilobases). Southern blot highstringency analysis demonstrated that the rat, guinea pig, and human genomes contain a single gene. As bradykinin is a key mediator of pain, knowledge of the primary structure of this receptor will allow a molecular understanding of the receptor and aid the design of antagonists for pain relief.
The nonapeptide bradykinin (Arg-Pro-Pro-Gly-Phe-Ser-ProPhe-Arg) is a mediator of pain, inflammation, vascular permeability, smooth muscle tone in vascular and other tissues, and gastrointestinal function (1) (2) (3) (4) (5) . Bradykinin can serve as a growth factor (2, 6, 7) . Bradykinin binds to G proteincoupled receptors that activate phospholipase C or phospholipase A2 and increases synthesis of inositol trisphosphate or arachadonic acid (8) (9) (10) .
Bradykinin receptors have been classified as two major subtypes, B1 and B2 (1) . The bradykinin metabolite des-Arg9-bradykinin is a B1 receptor agonist with potency greater than bradykinin, whereas it is inactive at B2 receptors. B2 receptors have been subdivided into two subtypes, a "neuronal" form, which is fully activated by [Thi58, DPhe7] bradykinin, where Thi is 83-(2-thienyl)-alanine, and a "smooth muscle" form, which is weakly activated by [This '8, DPhe7] bradykinin (11, 12) . Other subtypes of the B2 receptor have also been suggested (13, 14) .
The design of clinically useful bradykinin antagonists would be facilitated by knowledge of the primary structure of the bradykinin receptor. Because bradykinin has high affinity for both its receptor and its degradative enzyme, angiotensin converting enzyme, a full characterization of the receptor protein has been difficult (ref. 15 ; S.B. and K.J., unpublished work). Thus, we have used a clonal selection technique to isolate a cDNA clone encoding a smooth muscle, B2 bradykinin receptor (16) (17) (18) . ¶
MATERIALS AND METHODS
RNA Isolation. Total RNA was isolated from cells grown in culture by a modification of the method of Chomczynski and Sacchi (19) by using the reagent RNAzol (Cinna/Biotecx Laboratories, Friendswood, TX). Total tissue RNA was prepared as in Cathala et al. (20) . Poly(A)+ RNA was prepared by two passes over a column of oligo(dT) cellulose, type III (Collaborative Research).
Oocyte Preparation, Injection, and Electrophysiological Measurements. mRNA or cRNA was injected into collagenase-treated Xenopus laevis oocytes (usually 1 ng/nl for mRNA and library pools and 0.0075 ng/nl per clone 60; 40 nl per oocyte) as described in Zagotta et al. (21) . Whole-cell bradykinin-induced currents were measured 1-4 days later with a conventional two-microelectrode voltage clamp (Axoclamp 2A with virtual ground headstage; Axon Instruments, Burlingame, CA). Cells were continuously perfused, except when indicated, with 96mM NaCl/2 mM KCl/1.8 mM CaCl2/1 mM MgCl2/5 mM Hepes (pH 7.6) and 2.5 mM sodium pyruvate at room temperature. Membrane voltage was clamped at -60 mV to avoid rectification of the Ca2+-dependent Cl-current at more hyperpolarized potentials (22) . The clamp current recorded through the ten-times attenuated virtual ground was low-pass filtered with an eight-pole Bessel filter (Frequency Devices, Haverhill, MA), digitized at 10 Hz.
cDNA Library Construction. Rat uterus poly(A)+ RNA was sucrose-gradient fractionated (23) and then assayed after injection into oocytes for bradykinin-induced currents. Fraction C, enriched in 28 S RNA, contained the most activity and thus was used for cDNA library construction. The (30) . The computer-generated alignment was further adjusted by eye to maximize alignment of residues that are believed to be functionally equivalent. The consensus is calculated as the majority vote of the receptor sequences in Fig. 2 blocked the response and des-Arg9-bradykinin had no effect.
Based on the tissue distribution studies, a cDNA library was prepared in Lambda Zap II from sucrose-gradient sizefractionated poly(A)+ mRNA. The library of 100,000 individuals was screened by using six rounds of clonal selection to obtain a single clone, RUC15495-60 Bradykinin responses in oocytes injected with cRNA from the 1.9-kilobase (kb) fragment were identical to those seen in oocytes injected with the full-length clone (Fig. 1C) .
The predicted protein sequence of 366 amino acids has a molecular mass of 41,696 Da and is homologous to members of the seven transmembrane G protein-coupled family of receptors (Fig. 2) . Hydrophobicity analysis reveals seven putative transmembrane domains consistent with a seven transmembrane structure (40) . The largest overall degree of homology, 25% identity, is to the canine histamine-2 receptor (39). Reasonably strong homology, =23%, is observed to the neurotensin receptor and tachykinin receptors (substance P, substance K, and neuromedin K) and to the carboxyl-half of the luteinizing hormone/human chorionic gonadotropin receptor (17, 18, 31, 37) . Homology to the muscarinic receptors and adrenergic receptors and the visual rhodopsins is evident but less pronounced, 23-19%o (Fig. 2) . The sequence contains three potential N-linked glycosylation sites in predicted extracellular domains, two in the putative N-terminal extracellular domain, and one adjacent to a conserved cysteine (residue 186) in the second extracellular loop. This cysteine is a feature of most seven transmembrane receptors identified to date. In the 82-adrenergic receptor and bovine rhodopsin (41, 42) 
Cys-326 closely following transmembrane region 7 may anchor the receptor carboxyl tail to the plasma membrane through its palmitoylation because a homologous cysteine occurs in many members of this family and has been shown to be palmitoylated in both adrenergic receptors and rhodopsins (43, 44) .
Several workers have demonstrated that bradykinin receptor function is regulated by bradykinin, other hormones, second messengers, and their analogs (8, 45, 46) . In oocytes expressing clone 60, a second bradykinin bolus applied 3-5 min after a preceding identical dose yielded a smaller response; the second response to 10 nM bradykinin was 18 ± 6% (n = 10) of the first response, and the second response to 1 ,uM bradykinin was 7 ± 3% (n = 15) of the first response. This desensitization may involve several ofthe potential sites of receptor modification encoded by the cDNA, particularly those found in the third cytoplasmic loop and carboxyl tail.
Dose-response curves of bradykinin and its analogs were obtained by measurement of bradykinin-and analog-induced ion fluxes in oocytes injected with cRNA made from the 4.1-kb clone after verifying that downstream elements of the 20 40 60
Rat-Mus4 [Phe6]bradykinin and is very similar to that determined from competitive binding of these analogs to bradykinin receptor in CHAPS-solubilized rat uterus membranes (Table 1) . DesArg9-bradykinin (10 AM) had no effect on oocytes expressing the receptor (Fig. 1D) ; thus, the cDNA encodes a B2 rather than a B1 bradykinin receptor. Bradykinin stimulation of oocytes expressing the receptor was blocked by the antagonist [Thi5 8,DPhe7]bradykinin with an IC50 of400 + 240 nM (Fig. 3B and Fig. 1E ), which is similar to its pA2 of 6.3 (500 nM) measured for the inhibition of bradykinin-induced uterus contraction (47) and to its IC50 of 170 + 60 nM measured in competitive binding assays to CHAPS-solubilized receptor from rat uterus membranes. [Phe6]bradykinin "10,000 3600 ± 1200 The agonists did not significantly differ in the maximum response achieved (100-400 nA). Data were pooled from at least three separate experiments to include 3-62 oocytes per concentration. A full dose-response curve was not collected for [Phe6]bradykinin. Specific responses were not seen in clone 60-injected oocytes when the following substances were applied (at 1 AuM, unless indicated):
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substance P (n = 12); xenopsin (n = 3); Arg-vasopressin (n = 6); ranatensin (n = 3); bombesin (n = 7); carbachol (100 ,M; n = 5); and serotonin (n = 5). Substances that interact with angiotensin converting enzyme, the inhibitor SQ20,881 (10 AM; n = 13), and the substrate angiotensin I (n = 6) were ineffective.
compound indicates that clone 60 probably does not encode the subtype observed in the nerves ofthe rat vas deferens (11) oron neuroblastomaNlE-115 cells (12) 2), guinea pig (lanes 3 and 4) , and rat (lanes 5 and 6). The DNA was digested with EcoRI (lanes 1, 3, and 5) and HindIll (lanes 2, 4, and 6). (28) . The rat uterus has several times more receptor message than any other tissue or cell line tested (Fig. 4A) . mRNAs of 4.0, 5.7, and 6.5 kb were seen (Fig. 4A) . A 4.0-kb message is the most prominent in the uterus and is present in all tissues. A 6.5-kb band occurs only in uterus and kidney. All tissues except heart and testis have a 5.7-kb message. The existence of multiple mRNA species could be due to splicing precursors, variable length of polyadenylylation, alternate selection of polyadenylylation sites, or different subtypes of the receptor. The 4111-base cDNA is apparently a full-length clone of the 4-kb message.
A single gene highly homologous to the rat cDNA was seen in DNA from rat, human, and guinea pig by Southern blot analysis (Fig. 4B) . Drosophila melanogaster and X. laevis DNA showed no genes highly homologous to the rat bradykinin receptor.
The following lines of evidence suggest that a bradykinin receptor of the B2 smooth muscle subtype has been isolated: the rank order of potency of bradykinin and its analogs is similar to that reported for B2 receptors, des-Arg9-bradykinin is not an agonist, and [Thi5s8,DPhe7]bradykinin is a weak partial agonist and blocks bradykinin-mediated responses. In addition, mRNA tissue distribution studies are consistent with the described cDNA encoding a bradykinin receptor. The primary sequence of the described receptor places it in the seven transmembrane G protein-coupled receptor superfamily. The availability of this cDNA encoding a bradykinin receptor will allow better definition of coupling mechanisms, aid the identification of receptor subtypes, and allow investigation of structure-function relationships with the goal of designing specific and potent antagonists for the relief of pain.
